Nexalin Technology (NXL US): Synthetic Expert Call Transcript (11 Oct 2026)
Commercial traction remains constrained by zero insurance reimbursement and low volume, with Q2 2026 revenue printing at just $12.16 thousand...
84 Views
IPO Databook: Nexalin Technology (NXL US) - Oct 2026
Nexalin Technology, Inc. is a medical device company developing innovative neurostimulation products to address the global mental health...
82 Views
Quiddity Leaderboard ASX Sep25: Methodology Change Confirmed; Good Performance; Final Expectations
We have revised our final expectations for the September 2025 index review due to the deletion of Adriatic Metals which was one of our expected...
922 Views
No more insights